By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent and Chungnam National University today announced a collaboration targeting glycomics.

Under the terms of the deal, the partners will develop new applications, methods, technologies, and software tools for glycan analysis. The South Korean university hopes to identify and develop biomarkers for diseases, such as cancer, resulting in the development of therapeutic antibody products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.